FDMT
4D Molecular Therapeutics, Inc. Common Stock
stockNASDAQ
the mission of 4d molecular therapeutics is to design and develop transformative gene therapy products using our proprietary technology to create novel adeno-associated virus variants to be utilized as treatments for serious unmet medical conditions. our products are unlocking the full potential of gene therapy to treat, and potentially cure, genetic diseases. a large number of patients and diseases, who previously were not treatable by gene therapy, will be addressable by 4d products. 4d has one of the deepest and most diverse product pipelines in the gene therapy field. adeno-associated virus (aav) vectors have emerged as a favored delivery vehicle for gene therapy in the human body. they can deliver the genes for therapeutic proteins to accessible tissues in the body and are generally considered safe. several aav gene therapy products are in late-stage clinical development, and one product is approved in the eu (glybera, uniqure). however, these first-generation aav vectors have lim
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 14.56 | 2026-09-28 | -6.04% | -0.559 |
| 1M | 14.97 | 2026-09-04 | -8.62% | 1.323 |
| 3M | 12.72 | 2026-07-06 | +7.55% | 1.023 |
| 6M | 9.94 | 2026-04-06 | +37.63% | 1.294 |
| 1Y | 8.55 | 2025-10-03 | +60.00% | 1.921 |
| 2Y | 9.97 | 2024-10-04 | +37.21% | — |
| 5Y | 25.20 | 2021-10-04 | -45.71% | 1.281 |
4D Molecular Therapeutics, Inc. Common Stock (NASDAQ:FDMT) stock price today is $13.68, and today's volume is 1,036,924. FDMT is down 1.156% today. The 30 day average volume is 963,500. FDMT market cap is $755.74M with 55.24M shares outstanding.